Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

We present a cohort of 41 patients with osimertinib resistance biopsies, including two with an acquired CCDC6-RET fusion. While RET fusions have been identified in resistant EGFR-mutant NSCLC, their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Discov
Egile Nagusiak: Piotrowska, Zofia, Isozaki, Hideko, Lennerz, Jochen K., Gainor, Justin F., Lennes, Inga T., Zhu, Viola W., Marcoux, Nicolas, Banwait, Mandeep K., Digumarthy, Subba R., Su, Wenjia, Yoda, Satoshi, Riley, Amanda K., Nangia, Varuna, Lin, Jessica J., Nagy, Rebecca J., Lanman, Richard B., Dias-Santagata, Dora, Mino-Kenudson, Mari, Iafrate, A. John, Heist, Rebecca S., Shaw, Alice T., Evans, Erica K., Clifford, Corinne, Ou, Sai-Hong I., Wolf, Beni, Hata, Aaron N., Sequist, Lecia V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279502/
https://ncbi.nlm.nih.gov/pubmed/30257958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-1022
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak